Skip to main content

Caboxen 20 mg & 80 mg ( Cabozantinib)

Caboxen is presented as a cabozantinib medicine in 20 mg and 80 mg strengths. Cabozantinib is an oral targeted anticancer medicine used in selected cancer-treatment settings. Its dosage and administration depend on the exact formulation, treatment indication, and patient’s medical condition.

Cabozantinib treatment must be prescribed and supervised by a qualified healthcare professional. Patients should follow the instructions provided for their specific product and should never change their dose independently.

Understanding Caboxen Strengths

The stated Caboxen strengths are:

  • Caboxen 20 mg
  • Caboxen 80 mg

Strength indicates the amount of active ingredient in an individual dosage unit. It does not automatically represent the recommended daily dose.

The correct daily dose depends on the cancer being treated, the dosage form, the treatment plan, and individual patient factors.

An 80 mg product is not necessarily intended to be taken as one daily dose, and a 20 mg product is not necessarily intended for every patient. The prescribed regimen must be determined by the treating oncologist.

Recommended Cabozantinib Doses

Cabozantinib has different recommended doses depending on its formulation and indication.

The following examples describe reference products and must not be interpreted as confirmed Caboxen dosing instructions.

Cabozantinib Tablet Formulation

For the reference CABOMETYX tablet formulation, commonly specified adult doses include:

Treatment settingReference recommended dose
Advanced renal cell carcinoma, monotherapy60 mg once daily
Advanced renal cell carcinoma with nivolumab40 mg once daily
Hepatocellular carcinoma60 mg once daily
Differentiated thyroid cancer60 mg once daily
Certain previously treated neuroendocrine tumors60 mg once daily

Actual prescribing instructions depend on the applicable product information, treatment combination, patient characteristics, and regulatory approval.

Cabozantinib Capsule Formulation

The reference COMETRIQ capsule formulation has a different dosing regimen.

For its approved progressive metastatic medullary thyroid cancer indication, the reference adult starting dose is 140 mg once daily.

This capsule regimen must not be transferred to the tablet formulation or assumed to be the correct dose for Caboxen.

Important Difference Between Capsules and Tablets

Cabozantinib capsules and tablets are not bioequivalent and should not be substituted for one another.

Their strengths and administration instructions differ.

FeatureReference tablet productReference capsule product
ProductCABOMETYXCOMETRIQ
Available strengths20 mg, 40 mg, 60 mg20 mg, 80 mg
AdministrationOralOral
Fasting requirementAt least 1 hour before or 2 hours after foodAt least 2 hours before or 1 hour after food
InterchangeabilityNot interchangeable with capsulesNot interchangeable with tablets

The stated Caboxen strengths of 20 mg and 80 mg resemble the reference capsule strengths, but this does not establish that Caboxen is a capsule formulation.

Its exact dosage form must be confirmed before using any formulation-specific dosing or administration instructions.

How to Take Cabozantinib

Patients should take cabozantinib exactly as prescribed.

General administration considerations include:

  1. Confirm the exact product name and strength.
  2. Confirm whether the product is a capsule or tablet.
  3. Follow the prescribed dose and schedule.
  4. Observe the fasting instructions for the exact formulation.
  5. Swallow the medicine according to its product-specific instructions.
  6. Avoid changing the dose without medical advice.
  7. Keep the medicine stored according to its packaging instructions.

Patients should not crush, chew, split, or open a dosage unit unless the specific product information and healthcare professional explicitly permit it.

Should Cabozantinib Be Taken Before or After Food?

Food instructions depend on the formulation.

Reference tablet formulation: CABOMETYX tablets are generally taken on an empty stomach, at least one hour before eating or at least two hours after eating.

Reference capsule formulation: COMETRIQ capsules are generally taken on an empty stomach, at least two hours after eating and at least one hour before the next meal.

These fasting schedules are different. Patients must follow the instructions for their actual prescribed formulation.

What Happens If a Dose Is Missed?

The correct missed-dose instructions depend on the specific product information.

For the reference CABOMETYX tablet and COMETRIQ capsule labels, a missed dose that is remembered within 12 hours of the scheduled dose may generally be taken according to the applicable instructions. If more than 12 hours have passed, the missed dose is generally skipped and the next dose is taken at the usual time.

Patients should not take an extra dose to compensate for a missed dose.

When uncertain, patients should contact their pharmacist or treating healthcare professional.

What Happens If Too Much Cabozantinib Is Taken?

Taking more cabozantinib than prescribed may increase the risk of serious adverse reactions.

Possible concerns include severe diarrhea, dehydration, hypertension, gastrointestinal complications, and other toxicities.

Anyone who may have taken an excessive dose should seek immediate medical advice. Emergency medical assessment may be necessary depending on the amount taken and the patient’s symptoms.

Patients should not wait for symptoms to develop before seeking advice about a possible overdose.

Dose Adjustments During Treatment

Cabozantinib doses may need to be reduced, interrupted, or discontinued when serious adverse reactions occur.

A healthcare professional may consider dose modification in response to:

  • Severe or persistent diarrhea.
  • Significant hypertension.
  • Hand-foot skin reactions.
  • Liver-related complications.
  • Serious bleeding.
  • Gastrointestinal perforation or fistula.
  • Proteinuria.
  • Other clinically significant adverse reactions.

Dose modifications depend on the formulation, indication, severity of the adverse reaction, and applicable prescribing information.

Patients must not make these adjustments themselves.

Drug Interactions

Cabozantinib is metabolized partly through the CYP3A4 enzyme system.

Strong CYP3A4 inhibitors can increase cabozantinib exposure, while strong CYP3A4 inducers can reduce exposure.

Patients should tell their healthcare professional about all medicines and supplements they use, including:

  • Prescription medicines.
  • Non-prescription medicines.
  • Vitamins.
  • Herbal preparations.
  • Dietary supplements.

Some medicines and foods may affect drug metabolism. Patients should ask their healthcare professional about grapefruit and grapefruit-containing products before using them during treatment.

Precautions Before Starting Treatment

Before prescribing cabozantinib, healthcare professionals may assess:

  • Blood pressure.
  • Liver function.
  • Kidney function.
  • Urine protein.
  • Blood counts.
  • Cardiovascular history.
  • Bleeding risk.
  • Gastrointestinal conditions.
  • Dental health.
  • Previous or planned surgery.
  • Pregnancy status.
  • Other medicines being taken.

These assessments help identify possible risks and determine whether additional precautions are necessary.

Surgery and Dental Procedures

Cabozantinib can impair wound healing.

Patients should inform their healthcare team about planned surgery, invasive procedures, or dental treatment.

The treating healthcare professional may recommend temporarily interrupting treatment before certain procedures and restarting it only after adequate wound healing.

Patients should not decide independently when to stop or restart treatment.

Storage and Handling

Storage requirements should be taken from the packaging and official instructions for the exact product.

General precautions include:

  • Keep the medicine in its original packaging when appropriate.
  • Store it according to the stated temperature requirements.
  • Protect it from conditions that may damage the medicine.
  • Keep it away from children and pets.
  • Do not use expired or damaged products.
  • Avoid transferring medicine into another container unless advised by a pharmacist.

Caboxen-specific storage instructions should be confirmed from its actual product documentation.

Special Patient Groups

Patients With Liver Problems

Cabozantinib requires careful consideration in patients with impaired liver function. The appropriate treatment approach depends on the severity of impairment and the applicable product information.

Patients With Kidney Problems

Kidney function may need to be assessed before and during treatment. Patients should report changes in urination, swelling, or other concerning symptoms.

Pregnant Patients

Cabozantinib can cause fetal harm. It should not be used during pregnancy unless a specialist has made an appropriate medical assessment under the applicable prescribing guidance.

Women who could become pregnant should discuss effective contraception and the required precautions with their healthcare professional.

Breastfeeding Patients

Breastfeeding considerations should be discussed with the treating healthcare professional. Patients should follow the applicable product-specific recommendations.

Older Adults

Age alone does not determine the correct dose. General health, organ function, other medicines, and treatment tolerance should be considered.

Important Safety Warning

Cabozantinib can cause serious adverse reactions, including:

  • Severe bleeding.
  • Blood clots.
  • High blood pressure.
  • Gastrointestinal perforation.
  • Fistula formation.
  • Severe diarrhea.
  • Hand-foot skin reactions.
  • Impaired wound healing.
  • Osteonecrosis of the jaw.

Patients should promptly report concerning symptoms and seek emergency medical care for severe bleeding, chest pain, sudden breathing difficulty, severe abdominal pain, or sudden neurological symptoms.

Dosage and Administration Summary

Cabozantinib dosage is formulation-specific. The tablet and capsule reference products have different recommended doses, strengths, fasting requirements, and approved indications.

Although Caboxen is presented in 20 mg and 80 mg strengths, its exact dosage form and product-specific prescribing instructions must be confirmed before assigning a dosing regimen.

Patients should use Caboxen only as prescribed by a qualified healthcare professional and should never change the dose, formulation, or administration schedule without medical guidance.